The PAI-1 swing: Microenvironment and cancer cell migration;Microenvironnement cellulaire, PAI-1 et migration cancéreuse

Comptes Rendus - Biologies

Volumn 329, Issue 12, 2006, Pages 919-927

  Malo, Michel ^a   Charrière Bertrand, Cécile ^a   Chettaoui, Chafika ^a   Fabre Guillevin, Élizabeth ^a   Maquerlot, François ^a   Lackmy, Alexandra ^a   Vallée, Benoît ^a   Delaplace, Franck ^a   Barlovatz Meimon, Georgia ^a  

^a UNIVERSITY OF EVRY   (France)

Author keywords

Amoeboid migration; Matricellular protein; Nonlinear effects; PAI 1

Indexed keywords

CELL PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

CANCER; MICROMORPHOLOGY; MIGRATION; NONLINEARITY; PROTEIN;

ARTICLE; CANCER; CANCER CELL; CELL FUNCTION; CELL MIGRATION; CELL STRUCTURE; CELL TRANSFORMATION; METASTASIS;

EID: 33751274592     PISSN: 16310691     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crvi.2006.03.025     Document Type: Article

References (37)

1. Planus E., Barlovatz-Meimon G., Rogers R.A., Bonavaud S., Ingber D.E., and Wang N. Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading. J. Cell Sci. 110 9 (1997) 1091-1098
2. Bonavaud S., Charriere-Bertrand C., Rey C., Leibovitch M.P., Pedersen N., Frisdal E., Planus E., Blasi F., Gherardi R., and Barlovatz-Meimon G. Evidence of a non-conventional role for the urokinase tripartite complex (uPAR/uPA/PAI-1) in myogenic cell fusion. J. Cell Sci. 110 9 (1997) 1083-1089
3. Chazaud B., Ricoux R., Christov C., Plonquet A., Gherardi R.K., and Barlovatz-Meimon G. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am. J. Pathol. 160 (2002) 237-246
4. Duffy M.J., and Duggan C. The urokinase plasminogen activator system: A rich source of tumour markers for the individualised management of patients with cancer. Clin. Biochem. 37 (2004) 541-548
5. Umeda T., Eguchi Y., Okino K., Kodama M., and Hattori T. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J. Pathol. 183 (1997) 388-397
6. Greenburg G., and Hay E.D. Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J. Cell Biol. 95 (1982) 333-339
7. Cano A., Perez-Moreno M.A., Rodrigo I., Locascio A., Blanco M.J., del Barrio M.G., Portillo F., and Nieto M.A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2 (2000) 76-83
8. Lauffenburger D.A., and Horwitz A.F. Cell migration: a physically integrated molecular process. Cell 84 (1996) 359-369
9. Sahai E., and Marshall C.J. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat. Cell Biol. 5 (2004) 711-719
10. Friedl P. Prespecification and plasticity: shifting mechanisms of cell migration. Curr. Opin. Cell Biol. 16 (2003) 14-23
11. Wolf K., Mazo I., Leung H., Engelke K., von Andrian U.H., Deryugina E.I., Strongin A.Y., Brocker E.B., and Friedl P. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell Biol. 160 (2003) 267-277
12. Friedl P., Entschladen F., Conrad C., Niggemann B., and Zanker K.S. CD4+ T lymphocytes migrating in three-dimensional collagen lattices lack focal adhesions and utilize beta1 integrin-independent strategies for polarization, interaction with collagen fibers and locomotion. Eur. J. Immunol. 28 (1998) 2331-2343
13. Brakebusch C., Fillatreau S., Potocnik A.J., Bungartz G., Wilhelm P., Svensson M., Kearney P., Korner H., Gray D., and Fassler R. Beta1 integrin is not essential for hematopoiesis but is necessary for the T cell-dependent IgM antibody response. Immunity 16 (2002) 465-477
14. Nykjaer A., Petersen C.M., Moller B., Jensen P.H., Moestrup S.K., Holtet T.L., Etzerodt M., Thogersen H.C., Munch M., Andreasen P.A., and Gliemann J. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J. Biol Chem. 267 (1992) 14543-14546
15. Nykjaer A., Conese M., Christensen E.I., Olson D., Cremona O., Gliemann J., and Blasi F. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 16 (1997) 2610-2620
16. Keijer J., Ehrlich H.J., Linders M., Preissner K.T., and Pannekoek H. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator. J. Biol. Chem. 266 (1991) 10700-10707
17. Chapman H.A. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell Biol. 9 (1997) 714-724
18. Estreicher A., Muhlhauser J., Carpentier J.L., Orci L., and Vassalli J.D. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J. Cell Biol. 111 (1990) 783-792
19. Seiffert D., Mimuro J., Schleef R.R., and Loskutoff D.J. Interactions between type-1 plasminogen activator inhibitor, extracellular matrix and vitronectin. Cell Differ. Dev. 32 (1990) 287-292
20. Chazaud B., Bonavaud S., Plonquet A., Pouchelet M., Gherardi R.K., and Barlovatz-Meimon G. Involvement of the [uPAR:uPA:PAI-1:LRP] complex in human myogenic cell motility. Exp. Cell. Res. 258 (2000) 237-244
21. Wang N., Planus E., Pouchelet M., Fredberg J.J., and Barlovatz-Meimon G. Urokinase receptor mediates mechanical force transfer across the cell surface. Am. J. Physiol. 268 (1995) C1062-C1066
22. M. Malo, G. Gadea, C. Charrière-Bertrand, M. De Toledo, F. Maquerlot, E. Fabre-Guillevin, A. Lackmy, C. Anguille, D. Lawrence, P. Roux, G. Barlovatz-Meimon, Matrix PAI-1 directs tumour cell mode of migration (soumis)
23. Mitchison T.J., and Cramer L.P. Actin-based cell motility and cell locomotion. Cell 84 (1996) 371-379
24. Waltz D.A., Natkin L.R., Fujita R.M., Wei Y., and Chapman H.A. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest. 100 (1997) 58-67
25. Czekay R.P., and Loskutoff D.J. Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp. Biol. Med. (Maywood) 229 (2004) 1090-1096
26. Lazar M.H., Christensen P.J., Du M., Yu B., Subbotina N.M., Hanson K.E., Hansen J.M., White E.S., Simon R.H., and Sisson T.H. Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin. Am. J. Respir. Cell Mol. Biol. 31 (2004) 672-678
27. Wang Z., Sosne G., and Kurpakus-Wheater M. Plasminogen activator inhibitor-1 (PAI-1) stimulates human corneal epithelial cell adhesion and migration in vitro. Exp. Eye Res. 80 (2005) 1-8
28. F. Maquerlot, S. Galiacy, M. Malo, C. Guignabert, D. Lawrence, M.-P. d'Ortho, G. Barlovatz-Meimon, Dual role for PAI-1 (Plasminogen activator inhibitor type 1) as soluble and as matricellular regulator of epithelial alveolar cell wound healing, Am. J. Pathol. (sous presse)
29. Bornstein P., and Sage E.H. Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell Biol. 14 (2002) 608-616
30. Bornstein P., Agah A., and Kyriakides T.R. The role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury. Int. J. Biochem. Cell Biol. 36 (2004) 1115-1125
31. E. Fabre-Guillevin, M. Malo, H. Peinado, Bueno G. Moreno, J. Palacios, B. Vallée, A. Lackmy, F. Maquerlot, D. Lawrence, A. Cano, G. Barlovatz-Meimon, C. Charrière-Bertrand, Synergy between PAI-1 and SNAIL in tumoral process (soumis)
32. Bajou K., Noel A., Gerard R.D., Masson V., Brunner N., Holst-Hansen C., Skobe M., Fusenig N.E., Carmeliet P., Collen D., and Foidart J.-M. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4 (1998) 923-928
33. Harbeck N., Kates R.E., Gauger K., Willems A., Kiechle M., Magdolen V., and Schmitt M. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: Novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb. Haemost. 91 (2004) 450-456
34. Pedersen T.X., Pennington C.J., Almholt K., Christensen I.J., Nielsen B.S., Edwards D.R., Romer J., Dano K., and Johnsen M. Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas. Carcinogenesis 26 (2005) 1233-1240
35. Gatenby R.A., and Maini P.K. Mathematical oncology: cancer summed up. Nature 421 (2003) 321
36. C. Chettaoui, F. Delaplace, M. Manceny, M. Malo, Games network and application to PAs system, in: Information Processing in Cells and Tissues (conférences IPCAT 2005), Biosystems (sous presse)
37. Manceny M., Chettaoui C., Malo M., Barlovatz-Meimon G., and Delaplace F. Modéliser les interactions moléculaires par la théorie des réseaux de jeux. C. R. Biologies 329 (2006) 938-944